文献速递眼底病与葡萄膜炎

微视野作为结局指标提高RPGR基因治疗试验的患者入选与疗效检测

Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials.
PubMed 文献 · Am J Ophthalmol · 2026-06-12

该研究回顾性分析XIRIUS试验中15例RPGR相关视网膜病变患者第12个月数据,比较低亮度视力(LLVA)与微视野平均敏感度作为主要终点的表现。结果显示微视野检测到更高比例的治疗应答者(全网格45%,中央16点64%),而LLVA仅20%,且微视野允许更宽泛的患者入选。

要点

  • 微视野全网格应答率45%,中央16点达64%,均高于LLVA的20%。
  • LLVA因地板效应排除更多患者,限制了入选疾病窗口。
  • 微视野检测到LLVA未捕获的额外功能改善患者。

核心结论

  • 主要终点选择显著影响RPGR基因治疗试验的疗效检测和患者入选。
  • 微视野平均敏感度较LLVA更敏感、更具包容性,尤其当空间对齐治疗区域时。

研究设计与样本

  • 回顾性分析一项1/2期至3期干预性临床试验的单中心第12个月数据。
  • 纳入15例RPGR相关视网膜病变患者,一眼接受基因治疗,对侧眼为对照。

主要发现

  • 基线时LLVA因地板效应排除更多患者。
  • 第12个月,10例中2例(20%)满足LLVA应答标准。
  • 11例中5例(45%)满足EMA对齐的全网格微视野应答标准,包括所有LLVA应答者及3例额外功能改善患者。
  • 限制于中央16个微视野点,11例中7例(64%)被识别为应答者。
  • 微视野平均敏感度改善至少2.5 dB,超过预期重测变异;未治疗对侧眼无应答者。

关键数值与推荐

  • FDA对齐的LLVA应答标准:≥15字母增益。
  • EMA对齐的微视野应答标准:平均敏感度较基线改善≥2.5 dB。
  • 微视野评估使用完整68点MAIA网格及中央16点子集。

临床怎么用

  • 在RPGR基因治疗试验中,可优先考虑微视野平均敏感度作为主要终点,尤其空间对齐治疗区域。
  • 微视野可能扩大患者入选范围并更敏感地检测功能改善。

局限性

  • 回顾性分析,样本量较小(15例)。
  • 单中心数据,仅第12个月结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate how primary endpoint selection influences patient eligibility, enrolment, and detection of treatment efficacy in RPGR gene therapy trials, comparing low luminance visual acuity (LLVA) with microperimetry-based outcome measures. DESIGN: Retrospective analysis of a phase 1/2 to 3 interventional clinical trial. SUBJECTS: Fifteen patients were included in this study. Each was administered with gene therapy in one with the other eye serving as control. METHODS: Month 12 data from patients with RPGR-associated retinopathy enrolled at a single center in the XIRIUS trial (NCT03116113) were retrospectively analyzed. FDA-aligned low-luminance visual acuity (LLVA) responder criteria (≥15-letter gain) and EMA-aligned significant change from baseline in microperimetry mean sensitivity, were applied. Microperimetry outcomes were evaluated across the full 68-point MAIA grid and within a central 16-point subset. Minimal baseline inclusion thresholds were used. The proportion of gene therapy-treated patients meeting FDA- and EMA-aligned (≥2.5 dB improvement in mean sensitivity) responder criteria was determined. MAIN OUTCOME MEASURES: Proportion of patients meeting the responder criteria in either microperimetry or LLVA. RESULTS: At baseline, LLVA excluded more patients from study inclusion due to floor effects than microperimetry. At month 12, 2 of 10 patients (20%) met LLVA responder criteria. In contrast, 5 of 11 patients (45%) met EMA-aligned whole-grid microperimetry responder criteria, including all LLVA responders and 3 additional patients with clear functional improvement not captured by LLVA. Restricting analysis to the central 16 microperimetry points further increased responder detection, identifying 7 of 11 patients (64%). Improvements in microperimetry mean sensitivity of at least 2.5 dB, exceeding expected test-retest variability. No responders were identified for any endpoint in untreated fellow eyes. CONCLUSIONS: Primary endpoint choice substantially affects efficacy detection and patient inclusion in RPGR gene therapy trials. LLVA demonstrated limited sensitivity and restricted eligibility to a narrow disease window, risking underestimation of treatment benefit. Microperimetry mean sensitivity, particularly when spatially aligned with the treated retinal area, detected functional improvement in a substantially larger proportion of patients and supports broader enrolment. Microperimetry-based endpoints provide a more sensitive and inclusive primary outcome measure for RPGR gene therapy trials.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Josan AS, Taylor LJ, Raji S, et al. Microperimetry as an Outcome Measure Improves Patient Eligibility and Efficacy Detection in RPGR Gene Therapy Trials. Am J Ophthalmol. 2026. PMID: 42285469. doi:10.1016/j.ajo.2026.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。